HCP Education Portal
Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Adult: 8-Week Rapid Protocolized GC Dose Reduction, Including Long-term, 12-Month Data
Presented by
Gnangurudasam Prakasam,
MD
Medical Director
Sutter Medical Center
Presented on November 18, 2025
Patricia Stark: [00:00:10] Well, good afternoon. I’m Patricia Stark, the host for this afternoon’s broadcast. I would like to welcome you to the live presentation of Advancing Care in Classic Congenital Adrenal Hyperplasia (CAH): Study Insights from Catalyst Adult, Eight-Week Rapid Protocolized GC Dose Reduction, including Long-term, 12-Month Data. This afternoon’s broadcast is sponsored by Neurocrine Biosciences and presented by Dr. Gnanagurudasan Prakasam, Medical Director at Sutter Medical Center in Sacramento, California. Dr. P. serves as a paid consultant for Neurocrine Biosciences, Inc., and this promotional educational activity is sponsored by Neurocrine Biosciences, Inc., and is not certified for continuing medical education credit. The information presented is consistent with FDA guidelines. At the conclusion of the program, Dr. P. will be answering as many questions submitted by you, our audience, as possible. And you could submit a question by typing your question right into the chat box. And please do provide your name and email address along with your question, and we’ll follow up with you directly if we run out of Q&A time. Dr. P. will answer as many questions as time permits right up until the end of the program when I’ll be back to wrap up the broadcast.
Gnanagurudasan Prakasam, M.D.: [00:01:23] Thank you for introducing me and I hope I’ll keep it interesting for the next hour or so. Okay, so now that you’re all treating congenital adrenal hyperplasia, there’s nothing new. You all know that it’s autosomal recessive disorder. It’s actually a relatively common condition if you are an endocrinologist, one in 14,000 to one in 18,000 births. So a busy hospital will have about three or four newborns per year. And as you all know, in the U.S., we have the newborn screening program, so salt-wasting crisis, which we used to see quite often 30, 40 years ago, doesn’t exist anymore because they are able to catch that very early. As you all know, 95 percent of these patients are 21-hydroxylase deficient. And if you look at the pathway on the triangle over there, you will see that the stimulus come from hypothalamus. Then you have your corticotropin-releasing hormone acting on your pituitary gland, and which in turn secretes ACTH. And since there is a block at the level of adrenal gland, the cortisol as an attenuated feedback mechanism, which results in excessive production of ACTH, which results in excessive production of androgens.
[00:02:38] So pathology-wise, I’m sure you all recall this from your board exam days. Now with your recertification, it’s always nice to have a re-look at this. As you can see, you will have the blockage of 21-hydroxylase. So production of aldosterone and cortisol is reduced. That results in the bypass and your testosterone production and androstenedione and 17-hydroxyprogesterone increases because the pathway has to go somewhere, right? Okay, so what do we face? CAH has multiple comorbidities based on the age group we are dealing with. But one thing which is common all the time is the adrenal crisis. We always have to remember adrenal crisis with intercurrent illness, whether we like it or not, will exist. It’s a constant threat we can never forget when we’re managing CAH. So what do infants have? So if it is a female, it’s a relatively easy diagnosis because you have excessive secretion of male hormones resulting in atypical ambiguous genitalia whereas a male, it can be very difficult because they can present with salt-wasting crisis, adrenal crisis as their first presentation.
[00:03:55] Poor feeding and poor weight gain is common because of the salt-losing tendency with CAH. Now, when it comes to childhood, as we all know, the secretion of androgen has increased significantly. When that increases, your pubertal advancement goes faster, the bone age develops faster, you have accelerated growth, but you grow fast and you stop as well because the bones advance fast. So earlier on, they look very tall, but ultimately they lose a lot of adult height.
[00:04:25] When it comes to adulthood, it’s a combination of problems where the supraphysiologic doses of corticosteroids increases some comorbidities along with the excessive male hormones, so you have hypogonadism, impaired fertility, mood disorders, osteopenia, osteoporosis, short stature as we already discussed, increased CV risk because of steroids, females having hirsutism, acne, menstrual irregularities, PCOS, and males, testicular adrenal rest tumors, more common than what we think, and we’ll come to that slide in a few slides from now.
[00:05:02] Now, we all know we have managed CAH for a long period of time. It’s a balancing act all the time. Either you give too much steroids and then you suppress the androgen very well, but it’s supraphysiologic dose, you see side effects, then you try to reduce the steroids, the androgen level goes up, and then you deal with all the problems associated with that with hirsutism, PCOS, acne, so on and so forth. So it is always a balancing act all the time.
[00:05:35] So managing CAH, all of us will manage it for a long period of time. I have done it for 30-plus years now. Glucocorticoid therapy alone poses multiple challenges because supraphysiologic doses are required to bring the androgen secretion down. See, remember, physiologic dose of glucocorticoids is much lower than the supraphysiologic doses which are required to cut back the androgen levels, and a lot of us use the higher level because we use androstenedione and 17-hydroxyprogesterone as a way of looking at the pathway. So when you produce a lot of androgen, the only drug we had until now was to give extra steroids to suppress the pathway.
[00:06:23] Okay, so the limitations of glucocorticoid alone pathway is short-acting hydrocortisone fails to suppress androgen throughout the day. In fact, the night dose which we give in pediatric practice doesn’t even last all the way, and it’s even more attenuated. It lasts only five to six hours, so early morning high numbers are very common in the pediatric age group. And longer-acting glucocorticoids, which is more commonly used in adult practice like prednisone or dexamethasone, causes osteopenia, osteoporosis, so on and so forth, and we use it in our age group, which is growth suppression in pediatric group. So supraphysiologic dose, whichever way you look at it, yes, it might bring down the androgen levels, but the risk of long-term and short-term complications are plentiful.
[00:07:10] Now, we have CRENESSITY now. What can that do for us? See, remember, when we have this pathway which is very difficult to control, you have excessive production of corticotropin-releasing hormone that acts on the CRF1 receptors, which in turn stimulates the anterior pituitary gland to produce more ACTH. Excessive ACTH, in turn, produces more androgens.
[00:07:39] Now, with CRENESSITY, you can actually be a selective CRF1 antagonist, so it blocks the uptake of corticotropin-releasing hormone because CRENESSITY is competing along with it. When that happens, naturally, the CRF cannot stimulate the anterior pituitary gland, then it cannot produce excessive ACTH. It cannot produce excessive androgen. So, on the whole, you see a reduction in androgen production through the CRF1 antagonism, thus enabling us to reduce the glucocorticoid dose. So, glucocorticoid dose is needed in CAH, but that is not the only thing which is going to help you manage the patient better. That’s the take-home lesson.
[00:08:27] So, what does CRENESSITY do? It is indicated as an adjunctive therapy to glucocorticoid replacement to control androgens in both pediatric and adult populations, starting at the age of four years and above and the important contraindication is hypersensitivity reaction to CRENESSITY.
[00:08:47] Now, what can CRENESSITY help your patients with? Multifold. As a treating physician, you can look at multiple things. Now, if you’re seeing patients who already have a high level of male hormones, then reduce the androgen, or it can reduce the glucocorticoid, or it can reduce both. On the other hand, patients who already have a good androstenedione level, then you have to maintain the androgen by reducing the high dose of glucocorticoid, so it can act in either way.
[00:09:18] Let’s look at the studies which led on to the approval for this drug, right? So in pediatric practice, pediatric study, it was a personalized glucocorticoid reduction, whereas the adult study is a protocolized glucocorticoid reduction.
[00:09:35] Let’s see the study design. Initial screening was four weeks. A total of 182 patients were enrolled, one of the largest studies ever done in CAH population. It was a two-to-one randomization. It was double-blind, placebo-controlled, and it was a multicenter phase three trial. So 122 patients were in the CRENESSITY arm and 60 patients were in the placebo arm.
[00:10:01] So this was further divided into hypothesis one, where bringing down androgen was the main thing. So during the first four weeks, all of them received CRENESSITY or placebo BID dose. CRENESSITY was at 100 milligrams twice daily. And for a four-week period, the glucocorticoid dose was not adjusted. Whatever the doses the patients were on before was what was persisted. And the androstenedione levels and the 17-hydroxyprogesterone was measured. The second part of the hypothesis was divided into two phases. One is eight weeks of glucocorticoid reduction and 12 weeks of glucocorticoid optimization. What does that mean?
[00:10:40] During the glucocorticoid reduction phase, every patient who was on the study had a stepwise reduction of glucocorticoid dose to reach a target dose of eight to 10 milligrams per meter squared per day of hydrocortisone equivalent. So what is hydrocortisone equivalent? Whether you use prednisone or dexamethasone, we equalized using hydrocortisone equivalent over there. As you all know, for every one milligram of prednisone, it is about four or five milligrams of hydrocortisone, so both prednisone as well as dexamethasone are more potent drugs. So going back to the glucocorticoid optimization phase, that’s a 12 week phase where the glucocorticoids were adjusted based on the A4 levels, androstenedione levels. Okay? During the 28-week open-label treatment phase, all the patients got CRENESSITY.
[00:11:40] Okay, what happened during the study phase and the open-label phase? During the study phase, four to 12 weeks, all patients had their glucocorticoid doses reduced, irrespective of what the androstenedione dose was. The dose reduction was stepwise to reach a physiologic dose of 15 to 18 milligrams per day. And from weeks 12 to 24, glucocorticoid doses were more optimized based on androstenedione level. In the 28-week open-label phase, what they did was for the first four weeks, they did not adjust the glucocorticoids, but kept the glucocorticoid dose the same. And if the patients were taking more than 20 milligrams of glucocorticoid between weeks of 28 to 40, the doses were adjusted so that the androstenedione levels were either maintained or improved, and the glucocorticoid doses were reduced on an approximately monthly basis. And weeks 40 to 52, the doses were maintained.
[00:12:39] Now, 182 patients who were enrolled in the study, the key inclusion criteria was they had to have classic 21-hydroxylase CAH. Remember, the approval is for all classical congenital adrenal hyperplasia. However, during the study period, the patient enrollment was restricted to 21-hydroxylase deficiency. The patients should have been on supraphysiologic dose of glucocorticoids and the stable dosing at least for a month before screening and exclusion criteria if they were using steroids for any other reason, or if the glucocorticoids were already on overtreatment mode, or if they had a suspected diagnosis with something else.
[00:13:24] Okay, so basic characteristics was very similar between the CRENESSITY group and placebo group. Fludrocortisone was used in more than 85 percent of the patients, okay, alright. Medical conditions of interest, this is very interesting. During the study, we noted that testicular adrenal rest tumors were present in 66 percent of the patient population. That is two-thirds of the population. Same thing during the pediatric study, one-third of the population had that. So in our own practice now, all our male patients, if they had the disease for a few years, we started doing ultrasounds just to look at early stages of TART. It’s a good learning experience for us. Menstrual irregularities, hirsutism, acne, all of them were commonly observed in both the groups. And below that are all your comorbidities, which you see with steroids, which is osteopenia, anxiety, depression, hypertension, hyperlipidemia, so on.
[00:14:25] What was the efficacy data? Probably you already guessed based on the mechanism of action, right? Yes, that was absolute reduction in androstenedione. If you look at an average upper level of normal for androstenedione, it was 230, and from a baseline level of about 600, they were able to reduce it to half within four weeks. So a P-value, which was very powerful, less than 0.001 was observed in reduction of androstenedione levels, and as you could see in placebo, it actually went up a little bit.
[00:15:00] Same thing happened with your 17-hydroxyprogesterone. You wouldn’t expect any different because it blocks the production of androgens. And again, a very powerful statistical value bringing down from 9,000 plus to all the way down to 3,000, excellent endpoints on patients who are on CRENESSITY.
[00:15:20] Now, let’s look at the safety warnings. Number one, hypersensitivity reactions can occur. It occurred in one subject after three days of treatment and clinically significant hypersensitivity reactions, so initiated appropriate therapy and discontinued CRENESSITY. Like in any other drug, hypersensitivity reaction is something we all have to observe very closely.
[00:15:43] Other interesting pointer was the glucocorticoid dose reduction with CRENESSITY we were able to maintain all through the 52 weeks, not only during the first 24 weeks of placebo-controlled group, even after the 24 weeks, when they’re at open label, they were still able to show the constant glucocorticoid reduction.
[00:16:08] And what are the side benefits? When you reduce the corticosteroids, you tend to think, will there be effect on BMI and weight? And they did observe this. Again, this is only 52 weeks, more to come probably in future. But what was found was there was a reduction in BMI, there was a reduction in weight, and there was a reduction in insulin sensitivity. Again, too early to make major conclusions, but that was more than 5 percent weight loss was observed.
[00:16:39] Now, reduction of glucocorticoid dose to physiologic levels was way beyond the 24 weeks; 63 percent of adult patients in the CRENESSITY group achieved a glucocorticoid dose, which was in the physiologic range at 24 weeks while maintaining or improving A4 level. That’s the most important point. It’s not just about reduction of glucocorticoid dose, it’s about the fact that we were able to reduce the androstenedione and maintain that, and which was comparable to just 18 percent in the placebo group with, again, statistically very significant values over there. The percentage of adults with CRENESSITY who achieved the daily glucocorticoid dose in the physiologic range while maintaining or improving A4 levels was generally stable over 12 months. A lot of tongue twisters there, more than my name there, so apologies for that.
[00:17:35] Okay, CRENESSITY demonstrated efficacy across two distinct and critical aspects, androgen reduction, which we expected because there’s a block at that level, so androgen production is reduced, and because we are able to do that, we didn’t have to give higher dose of glucocorticoid, so glucocorticoid dose reduction more towards normalcy, more towards physiologic dose; 63 percent of patients with CRENESSITY achieved a glucocorticoid dose in the physiologic range while maintaining or improving A4 level. This percentage of adults on CRENESSITY who achieved glucocorticoid levels in physiologic range was generally stable over 12 months. So the data was good all-around when we looked at these patients.
[00:18:24] So safety data on protocolized glucocorticoid dose reduction. Okay, key thing, when we talk about CAH, we can never forget adrenal insufficiency or adrenal crisis, something we always have to remember. So risk of acute adrenal insufficiency and adrenal crisis with inadequate glucocorticoid therapy will always be present. So something we have to educate our patients on a regular basis, and appropriate stress dosing should be advised for these patients. Continuing glucocorticoid upon initiation and during CRENESSITY is very, very important, something we have to stress to our patients all the time. We are not substituting steroids. We are reducing steroids to a more optimal level by adding an additional drug. It’s not a replacement, it’s an adjunctive therapy. We have to continue to remind them of that. We have to continue to remind them of stress dosing as well.
[00:19:25] Now, a few adverse effects were noticed during that period, classified accordingly, but let’s look at what those adverse effects are. The commonly observed ones were fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia. In the pediatric study, there was a slight twist. The top most one was headache, followed by abdominal pain, and then fatigue. When you’re reducing the dose, the reduced amount of steroid leads on to that effect in many of them. There was no dose discontinuation, just based on that. And as you could see, when the patient went on to the extension phase of 24 to 52, you will see the fatigue, headache have all come down. During the double-blind period, 1.6 percent of patients taking CRENESSITY experienced adrenal crisis; 1.7 percent of patients taking placebo therapy experienced adrenal insufficiency. Acute adrenal crisis can occur in patients with underlying adrenal insufficiency, especially in situations associated with increased cortisol need, such as acute illness, serious trauma, or surgical procedures, something we can never forget, something we keep educating the patients all the time. Many of us who have done this for a long period of time, we know that we remind them very often, and that reminder becomes even more important when we are adding an adjunctive therapy and naturally reducing supraphysiologic dose. Even for all of us who have done this for a long period of time, using supraphysiologic dose is a very common way of suppressing androgen, and that is going to change. And that’s the reason we have to stress even more about how to protect the patients against adrenal insufficiency.
[00:21:25] Now, CRENESSITY has demonstrated safety and tolerability profile very well. The most common adverse reactions in adult patients, at least in 4 percent of the patients, as I already mentioned, was fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia. And a total of 3 percent of CRENESSITY-treated patients and no placebo-controlled patients discontinued treatment because of an adverse reaction of restlessness, apathy, dyspepsia, nausea, and vomiting. Important to notice, 96 percent of adults continued on CRENESSITY, that is 112 patients out of 117 and 96 percent of those patients were switched from placebo to CRENESSITY, also completed 28 weeks of open-label treatment. During the double-blind period, 1.6 percent of patients taking CRENESSITY experienced adrenal crisis, which we already mentioned. No patients on placebo experienced adrenal crisis. However, 1.7 percent experienced adrenal insufficiency.
[00:22:26] Okay, adverse effects, the most common adverse effects, again, we are reminding, are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia. And in pediatric patients, the most common adverse effect, as I mentioned already, started with headache, abdominal pain, then fatigue, nasal congestion, and epistaxis. We actively encourage you to report any negative side effects of prescription drugs to FDA. Visit MedWatch at www.fda.gov/medwatch or call the number 1-800-FDA-1088.
[00:23:18] Okay, we come to the summary slide. CRENESSITY reduces androstenedione levels and enables a reduced glucocorticoid dose while maintaining or improving A4 levels in adult patients. It’s a novel mechanism of action by selectively blocking function of CRF1, not CRF2, CRF1 receptors. CRENESSITY directly reduces ACTH and downstreams production of adrenal androgen. It is a proven efficacy because we saw during the hypothesis management, enables significant reduction in glucocorticoid dose while still maintaining or improving your androstenedione levels in adult patients with CAH. These glucocorticoid reductions were maintained through the 52 weeks. We had the new safety data published recently. CRENESSITY also significantly reduced A4 androstenedione levels at Week 4 and concurrently reduced 17-hydroxyprogesterone as expected, while glucocorticoid doses remain unchanged. Demonstration of safety was well seen and a few side effects which you had noted and we have repeated multiple times.
[00:24:32] Okay, let’s come to the dosing part now. You adult guys have it simple, okay? It’s capsules, 100 milligrams twice a day, twice daily with food. Pediatric practitioners have to think a little bit because children weighing less than 20 kilos, 10 to 20 kilos will use the oral solution, 25 milligrams twice daily, and in children between 20 to less than 55, capsules or oral solutions at 50 milligrams twice daily. You can use either capsules or oral solution. One thing is a must is that we have to use it along with food. And thank you, I’m going to stop here and open up for questions.
Patricia Stark: [00:25:15] Yes, thank you so much, Dr. P, very informative. That was wonderful. Another really warm welcome to Dr. P, that was terrific. Well, now it’s your turn, you have the floor. As a reminder, you can submit a question by typing your question into the chat box and please provide your name and email address along with your questions so we could follow up directly with you if we run out of time. So here comes our first question. Is there a recommendation for a specific time to monitor labs relative to dosing of GCs or CRENESSITY?
Gnanagurudasan Prakasam, M.D.: [00:25:45] Two part answer to this question. On a regular basis when you’re measuring, I would like to measure it at the trough time, which is before you gave the medications in the morning, so if you’re talking about timing of the medication. As far as subsequent levels, when are they checked? I like to check them every month when we are going through the process of dose adjustments. But once you have stabilized the glucocorticoid dose and you feel comfortable, then you do it every three months.
Patricia Stark: [00:26:14] Okay, excellent. Alright, our next question coming in, in your clinical experience, how is stress dosing affected after starting patients on CRENESSITY?
Gnanagurudasan Prakasam, M.D.: [00:26:22] I’m glad you guys asked this question because we mentioned that during the talk as well. Remember, when you’re using supraphysiologic dose, you have an inbuilt protection which is available all the time. Now you’re reducing this corticosteroid to a more physiologic level. What does normally happen? You have a physiologic dose and then there’s a supraphysiologic increase which happens at the time of stress. So you educate the patient to adjust the dose accordingly because it’s even more important now that their doses have been reduced and you have to revisit that multiple times. In the past, they might have forgotten to stress dose them for milder infections. Now they have to do that. So taking care of dosing, educating them on stress dose is very important. In our practice, we have made it a practice of talking about it every single time when we see a patient.
Patricia Stark: [00:27:18] Alright, very good. We have another question coming in. What types of classic CAH adult patients do you consider as candidates for CRENESSITY and why?
Gnanagurudasan Prakasam, M.D.: [00:27:27] So for us to do the balancing act, it’ll be better if we have two tools versus one tool. So I feel ultimately when all of us become more and more comfortable, it’ll become an automatic choice for us to start a patient on physiologic dose of corticosteroids and then an adjunctive therapy of CRENESSITY as soon as the diagnosis of a classical CAH is made. But in practice now, many of us look for patients who are using supraphysiologic dose or the androstenedione levels are too high or the male hormone profile is higher.
Patricia Stark: [00:28:07] Okay, alright, our next question. For endocrinologists who are not yet familiar with CRENESSITY, what would be the recommended approach for introducing it into clinical practice?
Gnanagurudasan Prakasam, M.D.: [00:28:15] Okay, the first important thing is for us to be comfortable that we are doing the right thing for our patients. So if you look at the mechanism of action, it’s clear for you to know it’s a very good adjunctive therapy. Once you take it to the next level, your first few patients, you want to start on those patients whom you trust will follow through on whatever you tell them to do. So let them be the first group of patients. Do a baseline level of your hormone profile. Do not change the doses at least for the first month of your corticosteroids. Leave at the same dose and add CRENESSITY 100 milligrams twice daily if you’re an adult patient. One month, do the levels. And once you see the androstenedione levels coming down, 17-hydroxyprogesterone coming down, you start discussing with the patients, hey, this is what your current dose is. I’m going to do a stepwise reduction of your glucocorticoids. There’s room for it. Let’s make sure you’re very conscious about stress dosing. I’m going to be seeing you more often. You cannot afford to miss your steroid therapy. I also would advise after one or two cycles to check renal panels and plasma renin activity because you want to look at the mineralocorticoid pathway as well because salt replacement and fludrocortisone reduces your risk for the symptoms of adrenal insufficiency.
Patricia Stark: [00:29:47] Alright, very good. Alright, next in, how should patients be monitored when CRENESSITY is introduced? How do you reduce GC doses?
Gnanagurudasan Prakasam, M.D.: [00:29:55] Okay, I think halfway through I mentioned that already. So patients who are started on CRENESSITY, at least in the initial few months, I would like them to be, say, either via telemedicine or in person every month. And then after the first month is when I would start reducing the dose. And that is based on your comfort level as a practicing physician. I would look at about 10 percent reduction at any given time going down on the hydrocortisone. I would suggest that we convert our patients to using hydrocortisone rather than dexamethasone or prednisone, which are a lot more potent, a lot more side effects. If you’re looking at the number of times you give dexamethasone, sorry, hydrocortisone, I would skip the nighttime dose first because that’s the most non-physiologic dose. So I would like to keep the morning dose and the afternoon dose and take away that. But remember, when there’s a time of stress, you want to do it three times or four times a day because hydrocortisone has a very short half-life.
Patricia Stark: [00:31:04] Okay, very good. Alright, our next viewer is asking, in your clinical experience, what results have you seen in your patients taking CRENESSITY?
Gnanagurudasan Prakasam, M.D.: [00:31:12] Touch wood, I’ve been very lucky so far. All my patients have done well. I mean, it’s still very early for me to tell will every patient be doing very well? But as for now, I’ve never had a patient who has discontinued therapy and they’re happy that they are taking it.
Patricia Stark: [00:31:29] Great news. Okay, historically, there have been limited treatment options for classic CAH patients that usually involved high doses of GCs. How does CRENESSITY offer potential change to that treatment paradigm?
Gnanagurudasan Prakasam, M.D.: [00:31:41] You don’t even know. I feel we are very lucky. For the longest period of time, that’s all we learned. You have congenital adrenal hyperplasia and you give steroids. And you give steroids, we just sometimes suppress that. And we never took interest in looking at what are we giving too much, because we didn’t have much of a choice. I feel it’s a blessing now that we have an adjunctive therapy which can actually act on the mechanism of action. The mechanism of action is so good that the supraphysiologic dose can be reduced. So it’s definitely a very good addition for us.
Patricia Stark: [00:32:16] Okay, terrific. Alright, the next question. In the double-blind portion of the trial, CRENESSITY showed significant reductions in daily GC doses. Were those changes maintained in the open-label period?
Gnanagurudasan Prakasam, M.D.: [00:32:28] Yes, you saw that in our extension study. Yes, it was maintained all through and it was very similar to what we saw in the first 24 weeks, so it’s very good.
Patricia Stark: [00:32:40] Alright, great. We have another question coming in. Did the common adverse events change during open-label long-term follow-up?
Gnanagurudasan Prakasam, M.D.: [00:32:45] No, it did not. Actually, it became better as time went by. In fact, the patients who have been on the study for a longer period of time, the fatigue and everything actually went away, felt very comfortable. And interestingly, I’ve been looking for my patients and I’m proactively asking them, and so far, that has not been a reason for them to say they don’t want to do that. A couple of patients have said the first couple of days they felt tired and they were fine after that.
Patricia Stark: [00:33:16] Okay. Alright, next, what is the biggest challenge in treating patients with CAH?
Gnanagurudasan Prakasam, M.D.: [00:33:21] The biggest challenge is making them partners. You want them to be educated what is available there. These patients go through a lot. They’re given a diagnosis and then they say there’s no cure available, right? And then they feel, okay, we are dumb, we don’t have to use steroids. Okay, I’m gaining weight or I’m getting insulin resistance or whatever, osteoporosis, they just live to accept that. Okay, which is the better of two evils? And now we are giving them hope. We are giving them confidence saying, okay, we can actually help you better. So creating that partnership is important. Making them feel it’s a privilege they give us to take care of them and we are not doing them a favor.
Patricia Stark: [00:34:03] That’s nice, very nice. Alright, next, how do you define a physiologic GC dose in clinical practice?
Gnanagurudasan Prakasam, M.D.: [00:34:09] I don’t know how to answer this question very effectively, but let me tell you this. The physiologic dose of glucocorticoid, physiologic growth levels is anywhere between two to 11 milligrams per meter squared in a normal person, right? So as far as practicing physicians, we typically use eight to 10 milligrams per meter squared as your physiologic dose. So we document it with every patient. You are talking about hydrocortisone equivalent, not dexamethasone or prednisone.
Patricia Stark: [00:34:44] Okay, alright, next, in your clinical practice, how would you address real-world lab monitoring in terms of types of labs and frequency?
Gnanagurudasan Prakasam, M.D.: [00:34:52] Okay, so types of labs and frequency, as I already mentioned, I would like to do it before the morning dose is given. And I like to do it every month until the dose reduction goes on and you reach you cannot go below the physiologic recommended dose, eight to 10 milligrams per meter squared is where you want to stop your dose reduction on hydrocortisone. You maintain that. After that, once you have reached the steady state, you can do it every three months. And I would definitely include a comprehensive metabolic panel to look at how the sodium levels are, how the potassium level is. I would like to do the plasma renin activity to look at the need of Florinef, whether the patient needs extra salt, so on and so forth. And remember, this is what we would do in our own clinical practice because each one of us are clinical clinicians, and in our practice, in my own practice, that’s what I would do.
Patricia Stark: [00:35:52] Okay, very good. Alright, we have one more question coming in. I think this might be our last one. What guidance should be given when talking to patients about stress dosing while on CRENESSITY? What guidance?
Gnanagurudasan Prakasam, M.D.: [00:36:03] I think throughout the lecture, we have been talking about the stress dosing and we’ll continue to remind them, stress dosing is important. You give them written documentation on what they want to do. The previous style of, if they are on hydrocortisone, just telling them double your dose, triple the dose may not be sufficient because they were on supraphysiologic dose. You want to give them specific instruction of what will be the ideal hydrocortisone dose for your practice, 20 milligrams, three times a day, which is what the majority of the adult practitioners use is what I would recommend in my practice. But again, you as clinicians should make your own decisions.
Patricia Stark: [00:36:41] Alright, Dr. P, thank you so much. What a pleasure to have you with us today.
Gnanagurudasan Prakasam, M.D.: [00:36:45] Thank you for having me.
Patricia Stark: [00:36:47] Well, that was the last question. Thank you all so much for submitting such insightful and thought-provoking questions. We do hope that you’ve thoroughly enjoyed this afternoon’s broadcast. On behalf of Neurocrine Biosciences, I’m Patricia Stark. Thank you so much for joining us. Take care.
Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Pediatric: Androgen and GC Dose Reduction Including Long-term, 12-Month Data
Presented by
Ian Marshall,
MD
Professor of Pediatrics
Chief, Division of Pediatric Endocrinology
Rutgers-Robert Wood Johnson Medical School
Presented on November 12, 2025
Patricia Stark: [00:00:10] Good evening. I’m Patricia Stark, the host for this evening’s broadcast. I would like to welcome you to the live presentation of Advancing Care in Classic Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Pediatric: Androgen and GC Dose Reduction Including Long-term, 12-Month Data. This evening’s broadcast is sponsored by Neurocrine Biosciences and presented by Dr. Ian Marshall, Professor of Pediatrics and Chief of the Division of Pediatric Endocrinology at Rutgers-Robert Wood Johnson Medical School. Dr. Ian Marshall has received research funding from and serves as a paid consultant for Neurocrine Biosciences Inc., on behalf of Rutgers-Robert Wood Johnson Medical School, but does not receive personal income for these activities. This promotional educational activity is sponsored by Neurocrine Biosciences Inc. and is not certified for continuing medical education credit. The information presented is consistent with FDA guidelines. At the conclusion of the program, Dr. Marshall will be answering questions submitted by you, our audience. And you could submit a question by typing your question into the chat box. And please do provide your name and email address along with your question, and we’ll follow up with you directly if we happen to run out of Q&A time. Dr. Marshall will answer as many questions as time permits right up until the end of our program, when I’ll be back to wrap up the broadcast. All right. Let me hand it off to Dr. Marshall to briefly review this disease state. Take it away, Dr. Marshall.
Ian Marshall, M.D.: [00:01:43] Thank you very much, and thank you for joining us today. CAH is a serious, rare autosomal recessive disorder that is difficult to manage and treat. The worldwide incidence of classic CAH is approximately one in 14,000 to one in 18,000 live births. Approximately 95 percent of classic cases are due to a mutation that leads to deficiency of the 21-hydroxylase enzyme. This is an adrenal-specific enzyme required for cortisol and aldosterone production. Attenuated cortisol-mediated negative feedback allows excessive CRF drive and ACTH secretion, which leads to excessive production of adrenal androgens and enlarged adrenal glands.
[00:02:28] This is a composite slide of the steroid pathways in the adrenal gland. 21-hydroxylase is a critical enzyme in the steroidogenesis of cortisol and aldosterone in the adrenal gland. It converts progesterone to deoxycorticosterone, which is a precursor to aldosterone. It also converts 17-hydroxyprogesterone, or as we term it, 17-OHP, to deoxycortisol, the precursor to cortisol. Thus, a deficiency in 21-OH results in deficiency in the synthesis of both cortisol and aldosterone. So what happens is 17-OHP accumulates prior to the block and is metabolized by the only available pathways to androstenedione or A4 and the active androgen testosterone. As a result, these steroids are typically measured to assess disease control and treatment adequacy.
Patricia Stark: [00:03:20] So, doctor, in your experience, what challenges have you noted in your patients with CAH?
Ian Marshall, M.D.: [00:03:26] Well, in addition to the risk of adrenal crisis, people with CAH may, unfortunately, face multiple challenges and comorbidities throughout their lives. In infancy, there’s atypical genitalia in female patients. There’s also a high risk of salt wasting in adrenal crisis. There can be poor feeding and poor weight gain. In childhood, due to chronic hyperandrogenemia, there can be accelerated growth, early pubertal development and advanced bone maturation and early fusion of growth plates. Due to chronic GC exposure, there can be poor growth and weight gain, leading to overweight and obesity. In adulthood, due to chronic GC exposure, there can be mood disorders, osteopenia and osteoporosis, and increased cardiovascular risk, the second most common cause of mortality in the classic patients. Due to chronic hyperandrogenemia, there can be hypergonadism and impaired fertility. In males, there can be TARTs, or testicular adrenal rest tumors, that develop in the testes of these patients. In females, you may see hirsutism, acne, and menstrual irregularities as well as polycystic ovarian syndrome.
[00:04:36] Now managing CAH with GC-only therapy presents multiple challenges. GCs are not ideal for managing adrenal androgen excess. High or supraphysiologic GC doses indirectly manage adrenal androgens by lowering CRF or corticotropin-releasing-factor release. This leads to reduced CRF1 receptor activation on the anterior pituitary gland, reduces ACTH release from that pituitary and then lowers adrenal androgens. There are other limitations to GC-only therapy that result in suboptimal disease control. Short-acting hydrocortisone fails to suppress androgens throughout the day and often requires multiple dosing. Long-acting GCs like dexamethasone can lead to growth issues in pediatric patients as well as metabolic abnormalities in adult patients. There is non-physiologic coverage, and continued ACTH excess can occur despite supraphysiologic dosing by GCs. It is important to remember that with supraphysiologic doses of GCs, there are risks for short and long-term comorbidities.
[00:05:45] So onto CRENESSITY. CRENESSITY is a potent and selective CRF1 antagonist that directly prevents excess ACTH at the source. These receptors are located on the anterior pituitary gland. When activated, they stimulate the release of ACTH from the anterior pituitary gland. Thus CRF1 antagonist prevents the ACTH release, directly managing excess ACTH. Less ACTH in turn reduces stimulation of the adrenal glands, subsequently decreasing downstream adrenal androgen secretion. This could also bring GC dose reductions closer to physiologic levels in patients with classic CAH.
[00:06:26] Now let’s review CRENESSITY Important Safety Information. CRENESSITY, or crinecerfont, which is the generic name, is indicated as adjunctive treatment to GC replacement to control androgens in adults and pediatric patients four years or older with classic CAH. Contraindications. CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients in CRENESSITY.
[00:06:56] CRENESSITY can help patients reach their goals. For patients with androstenedione levels above the upper limit of normal, those with suboptimal control, the goals may include reducing those androgens, reducing high GC doses, or a combination of both by reducing high androgens and high GC doses. For patients with A4 levels within the appropriate range, the goal may be maintaining those androgens in that range and reducing high GC doses.
[00:07:25] So let’s talk about the CAHtalyst pediatric study. So the CAHtalyst pediatric study was a randomized, double-blinded, placebo-controlled Phase 3 trial with two hypotheses. Hypothesis 1 was CRENESSITY can reduce A4 while holding GC dose stable. Hypothesis 2 was CRENESSITY-induced reduction in A4 enables treatment with lower GC dosing while maintaining or improving A4 levels relative to Day 1 baseline. On Day 1, patients were randomly assigned in a 2:1 ratio to receive CRENESSITY or placebo twice daily with morning and evening meals. One hundred and three patients were enrolled, 69 patients to the CRENESSITY group and 34 to the placebo group. CRENESSITY was dosed as 25 milligrams, 50 milligrams or 100 milligrams twice daily based on age and weight.
[00:08:15] GC regimens were maintained from baseline to Week 4 during the stable period. Then from Week 4 through 28, the glucocorticoid dose was adjusted in one to four steps to a target of eight to 10 milligrams per square meter per day in hydrocortisone equivalents. This was known as the GC adjustment period, but provided that A4 level was maintained. And this was defined as a level that was below or equal to either 120 percent of the baseline A4 level or the upper limit of the normal range. This double-blind phase was followed by 24-week open-label treatment period. During this 24-week period, 96 percent of patients continued CRENESSITY while 91 percent switched from placebo to CRENESSITY orally twice daily.
[00:09:04] For patients who switched from placebo to CRENESSITY, GC doses were first not changed for the first four weeks, from Weeks 28 to 32. But for patients taking greater than 11 milligrams per square meter per day, GC doses were reduced beginning at Week 32, only when A4 levels were maintained or improved. GC doses were reduced on an approximately monthly basis to reach a more physiologic range of between eight to 10 milligrams per square meter per day.
[00:09:32] In the double-blind phase of the trial, GC dose reduction was personalized. Doses were reduced only when A4 levels were maintained or improved, defined as less than or equal to 120 percent of baseline values or less than or equal to the upper limit of normal for sex and either age for Tanner Stage 1 or for pubertal stage Tanner Stage 2 to 5. GC doses were adjusted in one to four steps to reach a more physiologic range of eight to 10 milligrams per square meter per day. Patients unable to maintain or improve A4 levels with a GC dose reduction were considered to have 0 percent change in daily GC dose. During the 24-week open-label period, for patients who switched from placebo to CRENESSITY, GC doses were not changed for the first four weeks. For patients taking greater than 11 milligrams per square meter per day, GC doses were reduced beginning at Week 32 only when androstenedione levels were maintained or improved. And again, GC doses were reduced about every month to reach a more physiologic range.
[00:10:35] One hundred pediatric patients completed the double-blind study. Pediatric patients had to have parental or legal guardian informed consent with signed and witnessed study subject ascent. The key inclusion criteria included the following: two to 17 years of age, however, the youngest patient enrolled was four years of age, medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency based on 17-OHP levels, confirmed genotyping or diagnostic results from ACTH stimulation testing. They had to be on supraphysiological dosing, more than 12 milligrams per square meter per day for at least one month prior to screening. They had to have A4 levels prior to the morning GC dose greater than the midpoint of the reference range based on Tanner stage, and 17-OHP levels greater than two times upper limit of normal based on Tanner stage. Key exclusion criteria included known or suspected diagnosis of another form of classic CAH, such as 11-beta-hydroxylase deficiency. Clinically significant medical conditions or chronic disease that would interfere with study endpoints were excluded. History of bilateral adrenalectomy, hypopituitarism or other conditions requiring chronic daily therapy with oral glucocorticoids and those at risk for developing adrenal crisis.
[00:11:59] Baseline characteristics were well balanced between the CRENESSITY and placebo groups and included a broad range of patients who represent the CAH population. Baseline comorbidities highlight the challenge of effectively treating CAH with GCs alone.
[00:12:16] The number and percentage of participants with self-reported medical conditions of interest indicated by yes responses, study entry are presented here. Of note, 46 male participants had available testicular sonogram assessment at baseline. TARTs were reported in 6 percent of the male participants, but were identified in 33 percent who underwent the baseline sonography.
[00:12:39] Now let’s talk about the efficacy data of the study.
[00:12:44] The primary endpoint was serum A4 levels at Week 4 compared to baseline. And as you can see, the CRENESSITY group had an average of 197 nanograms per dL reduction in serum A4 levels at Week 4 compared to an actual 71 nanograms per dL increase with placebo. Now this was statistically significant with a P-value of less than 0.01, indicating that the study met its primary endpoint. The key secondary endpoint was serum 17-OHP levels again at Week 4 compared to baseline. The CRENESSITY group had an average of 5,865 nanogram per dL reduction in serum OHP levels at Week 4 compared to an increase of 556 nanograms per dL in the placebo group. This was again statistically significant with a P-value of less than 0.001 and met its key secondary endpoint.
[00:13:39] At Week 28, after adjustments in the glucocorticoid dose, the mean A4 and 17-OHP levels remained below baseline in the CRENESSITY group, but as you can see, A4 was above baseline in the placebo group.
[00:13:53] Now, to discuss warnings and contraindications. Risk of acute adrenal insufficiency or adrenal crisis with inadequate concomitant glucocorticoid therapy. Acute adrenal insufficiency or adrenal crisis, which are potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily GC dosing, especially in situations associated with increased cortisol need, such as acute intercurrent illnesses, serious trauma or surgical procedures. Glucocorticoids should be continued upon initiation of and during treatment with CRENESSITY. Do not reduce the GC dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in case of increased cortisol need.
[00:14:40] Another key secondary endpoint was the change in mean GC daily dose from baseline to Week 28 while maintaining A4 level. Among participants assigned to receive CRENESSITY, the GC dose was reduced from baseline to Week 28, while control of androstenedione level was maintained during that time, whereas the dose in the placebo group was increased. The mean percent change from baseline in the CRENESSITY group was minus 18 percent versus plus 6 percent in the placebo group. This was a least squares mean difference of minus 23.5 percentage points, which again was statistically significant at a P-value less than 0.001. And these GC dose reductions with CRENESSITY were maintained through the 52-week open-label period. It should be noted that this pre-specified exploratory endpoint was not adjusted for multiplicity and that these descriptive results could represent chance findings.
[00:15:38] Among CRENESSITY-treated participants, 30 percent, 20 of 67, achieved a physiologic GC dose of less than or equal to 11 milligrams per square meter per day at Week 28 with maintenance of A4 control as compared to zero participants in the placebo group. The percentage of children on CRENESSITY who achieved physiologic GC dosing while maintaining or improving A4 levels remain stable at 52 weeks. These endpoints were not adjusted for multiplicity, and these descriptive results could represent chance findings as well.
[00:16:12] Another secondary endpoint was the change from baseline for body mass indices at Week 28. And what this shows is that patients treated with CRENESSITY saw reduction in BMI Week 28, and these results were maintained at Week 52. These endpoints are presented as LSM change from baseline at Week 28 and as mean change at Week 52. These secondary and pre-specified exploratory endpoints were not adjusted for multiplicity again, and these results could represent chance findings.
[00:16:44] In summary, CRENESSITY demonstrated efficacy across two distinct and critical aspects of CAH management. CRENESSITY significantly reduced A4 and 17-OHP levels at Week 4 while holding the GC dose stable. Further, CRENESSITY resulted in a four times greater reduction in daily GC dosing versus placebo at 28 weeks while maintaining or improving A4 levels relative to Day 1. GC dose reductions with CRENESSITY were maintained through 52 weeks, and 30 percent of participants treated with CRENESSITY were able to achieve a physiological dose of GC by Week 28 versus 0 percent on placebo. A similar percentage of patients achieved a physiologic GC dose after long-term, 12 months of CRENESSITY treatment.
[00:17:33] Now the safety data from the CAHtalyst pediatric study is very interesting.
[00:17:38] Now, to discuss warnings and precautions, particularly hypersensitivity reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after three days of treatment with CRENESSITY. If a clinically significant hypersensitive reaction occurs, you should initiate appropriate therapy and discontinue CRENESSITY.
[00:18:02] The following table depicts treatment-emergent adverse events experienced with CRENESSITY. The percentage of participants who had adverse events that emerged during the treatment period was similar in the two groups, 84 percent in CRENESSITY, and 82 percent in the placebo group. And most adverse events were mild to moderate in severity. The total of 3 percent of CRENESSITY-treated subjects and no placebo-treated subjects discontinued treatment because of adverse reactions of abdominal pain, myalgia, and dizziness during the double-blind phase. No deaths occurred during this trial period.
[00:18:40] This table shows adverse reactions that occurred in pediatric patients over 52 weeks. With an incidence of greater than or equal to 4 percent in the CRENESSITY group and more frequent than placebo, patients taking CRENESSITY had no treatment-related serious adverse reactions, and most adverse reactions were mild to moderate. There were no additional safety concerns related to vital signs, clinical lab values, EKG findings, or neuropsychiatric assessments with CRENESSITY in the Phase 3 trial. And no new safety signals were observed in the open-label period. During the double-blind period, there were no incidents of adrenal crisis across both arms. During the open-label period, there was one incidence of adrenal crisis among those who switched to the CRENESSITY arm. This resolved and was judged by the investigator not to be related to CRENESSITY. Of note, acute adrenal crisis can occur in patients with underlying adrenal insufficiency, especially in situations associated with increased cortisol needs such as acute illness, serious trauma or surgery.
[00:19:47] In summary, CRENESSITY has demonstrated safety and tolerability profile in pediatric patients with no treatment-emergent serious adverse events. The most common adverse reactions for pediatric patients are headache, abdominal pain, fatigue, nasal congestion, and epistaxis. Both during and after the double-blind phase of the trial, three percent of patients taking CRENESSITY and no patients taking placebo discontinued due to an adverse reaction. Ninety-eight percent of children who continue CRENESSITY and 100 percent of those who switched from placebo to CRENESSITY completed the 24-week open-label treatment. No adrenal crises were reported in pediatric patients being treated with CRENESSITY.
[00:20:34] Now, regarding adverse reactions, in pediatric patients, the most common adverse reactions, again, greater than or equal to 4 percent for CRENESSITY and greater than placebo are headache, abdominal pain, fatigue, nasal congestion, and epistaxis. In adult patients, the most common adverse reactions are fatigue, headache, dizziness, decreased appetite, and myalgia. You are encouraged to report negative side effects of prescription drugs to the FDA as mentioned below through the web address or through the 800 number.
[00:21:09] Therefore, in summary, CRENESSITY directly reduces ACTH and the downstream production of adrenal androgens by selectively blocking the function of CRF1 receptor. CRENESSITY enables significantly reduced GC daily dose while maintaining or improving A4 levels in patients with CAH. CRENESSITY also significantly reduced androgen and androgen precursor levels as measured by A4 and 17-OHP at Week 4, while GC doses remained unchanged. Androgen levels maintained or improved relative to Day 1 baseline at Week 28. GC dose reductions with CRENESSITY were maintained through 52 weeks. The most common adverse reactions in pediatric patients are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.
[00:22:00] Now, a couple of thoughts about dosing. You’ll find key CRENESSITY dosing information here. Dosing for CRENESSITY is based on age and weight of the patient. CRENESSITY is available as 50 and 100 milligram capsules and has an oral solution of 50 milligrams per mL. And these are for the younger children. No additional adjustments are required for concomitant use of other CYP or transporter inhibitors or inducers. CRENESSITY must be taken with a meal twice daily to aid absorption so that you can optimize 24-hour ACTH and androgen suppression. And as mentioned, must be taken with a meal to aid absorption and should be taken in the morning and evening and can be timed with GC dosing. Now, very importantly, CRENESSITY does not address the cortisol deficiency. Patients prescribed CRENESSITY should continue taking the GCs to replace their missing cortisol, but can take it at lower doses if possible.
Patricia Stark: [00:22:58] Thank you very much, Dr. Marshall, for all that great information. Now it’s your turn. You have the floor. As a reminder, you can submit a question by typing your question into the chat box. And please provide your name and email address along with your question, and we’ll follow up with you directly if we run out of Q&A time. So let’s take our first question. Here it is. Is there a recommendation for a specific time to monitor labs relative to dosing of GCs or CRENESSITY?
Ian Marshall, M.D.: [00:23:26] Well, that’s an excellent question. So historically, we’ve always checked the androgen levels after the morning dose at the peak action of hydrocortisone. But based on the study and now, and in my clinical practice, I am checking androgen levels before the morning dose. This gives us a better reflection of the action on CRENESSITY.
Patricia Stark: [00:23:46] Alright. We have another question coming in. In your clinical experience, how is stress dosing affected after starting patients on CRENESSITY?
Ian Marshall, M.D.: [00:23:53] Well, it’s very important to emphasize that we have to maintain appropriate doses of glucocorticoids at a physiologic range, at least on these patients. And we need to stress dose appropriately in the way we did before. And it’s very important that we pay careful attention to that.
Patricia Stark: [00:24:11] Alright. We have another audience question. What types of classic CAH pediatric patients do you consider as candidates for CRENESSITY, and why?
Ian Marshall, M.D.: [00:24:19] So I always think of my classic CAH patients in three buckets. And the first bucket, which is the majority of my patients, are the patients with supraphysiologic dosing, but poor control. So these were the first patients I would choose. Another bucket that we can choose are those with good control, but supraphysiologic dosing where we can reduce the GC doses.
Patricia Stark: [00:24:41] Alright. Here comes our next question. For pediatric endocrinologists who are not yet familiar with CRENESSITY, what would be the recommended approach for introducing it into clinical practice?
Ian Marshall, M.D.: [00:24:51] Well, I think the important thing is to identify the patients that would be best served by this medication and benefit from this medication. So after prescribing the medication and starting the medication, about four weeks later, what I’ll do is I’ll check the androgen levels again. At baseline, I’ll be checking them before the morning dose. Four weeks later on CRENESSITY without GC dose changes, I’ll check the androgen levels again. After I’ve reviewed these androgen levels, which should be decreased, I’ll then start decreasing the glucocorticoid dosing. And the way we do this is we want to be relatively conservative with this and reduce it at maybe 20 percent or 25 percent each month or every two months.
Patricia Stark: [00:25:34] Okay. Alright. A lot of good questions coming in. How should patients be monitored when CRENESSITY is introduced? How do you reduce GC doses?
Ian Marshall, M.D.: [00:25:41] So as I mentioned, what we would do is I would check the androgen levels at least four weeks after starting the CRENESSITY as was done in the study. Then based on those results, my approach would be, should I, and can I lower the GC dosing? What I like to do and what we, we like to do in clinical practice, about every one or two months, it depends how conservative you wanna be. You start lowering the glucocorticoid dosing. Now you can lower the total dose per square meter per day, or you can certainly lower an evening dose first to make it more physiologic in the end, in the end for these medications.
Patricia Stark: [00:26:21] Alright. Alright. Our next viewer would like to know in your clinical experience, what results have you seen in your patients taking CRENESSITY?
Ian Marshall, M.D.: [00:26:28] So, so far, I’ve seen excellent results. After four weeks, I’ve seen all my patients decrease their androgens, and I’ve been able to reduce glucocorticoid dosing in the majority of my patients. They’re all different phases of treatment, so some of them have been further in the treatment, but overall, they’re all doing very well.
Patricia Stark: [00:26:47] Okay. Very good. Alright. Here’s another question. Historically, there have been limited treatment options for classic CAH patients that usually involved high doses of GCs. How does CRENESSITY offer a potential change to that treatment paradigm?
Ian Marshall, M.D.: [00:27:01] So one of the most debilitating comorbidities associated with CAH—with classic CAH—are the high glucocorticoid dosing, which can affect children and adults in multiple ways. So what this allows us to do, this is a new paradigm of care. This allows us to significantly reduce glucocorticoid dosing so that the glucocorticoid exposure over years is reduced and reduces the risk for comorbidities.
Patricia Stark: [00:27:30] Okay. Alright. Very good. Our next question. In the double-blind portion of the trial, CRENESSITY showed significant reductions in daily GC doses. Were those changes maintained in the open-label period?
Ian Marshall, M.D.: [00:27:42] So during the double-blind phase at Week 28, there was an 18 percent reduction in glucocorticoid dosing in the CRENESSITY-treated group. And this was maintained at around 17 percent at the end of the open-label study.
Patricia Stark: [00:27:56] Okay. Alright. Very good. Our next question, did the common adverse events change during open-label long-term follow-up?
Ian Marshall, M.D.: [00:28:03] There were changes and there are actually changes to the positive because there’s decrease in the incidence of these adverse events while on the CRENESSITY on a longer basis.
Patricia Stark: [00:28:13] Okay. Very good. Alright. Another question coming in. What’s the biggest challenge in treating pediatric patients with CAH?
Ian Marshall, M.D.: [00:28:19] So as a pediatric endocrinologist, I like to think that pediatric patients and their families are less challenging. And one of the main reasons is we are actually dealing with parents that can ensure compliance, can really report on their kids. And dealing with adult patients, you’re dealing with the patient themselves. The important thing is to make sure you transition their care appropriately from pediatric patients to adult patients.
Patricia Stark: [00:28:44] Okay. Alright. Next up, how do you define physiologic GC dose in clinical practice?
Ian Marshall, M.D.: [00:28:50] Well, I would define it exactly as we did in the study, that glucocorticoid dosing per milligram per square meter per day would be less than 11 milligrams per square meter per day.
Patricia Stark: [00:29:01] Okay. Alright. Excellent. Let’s see. In your clinical practice, how would you address real-world lab monitoring in terms of types of labs and frequency?
Ian Marshall, M.D.: [00:29:10] So in my clinical practice, as mentioned, what I would do at baseline is measure 17-OHP and A4 levels. This would be done before the morning GC dose. Four weeks later, I would measure the same markers before the morning dose, and these are the markers that I would measure every time I’m checking this child to ensure the efficacy of the glucocorticoids as well as the CRENESSITY.
Patricia Stark: [00:29:35] Okay. Alright. I think we have time for one more question. What guidance should be given when talking to patients or caregivers about stress dosing while on CRENESSITY?
Ian Marshall, M.D.: [00:29:43] Well, it remains essential for caregivers and patients to recognize those stresses that can cause, that can cause adrenal crisis, such as acute intercurrent illnesses, surgery, and trauma. And they should ensure with their doctor what doses they should stress dose with, if they should double the dose or triple the dose or continue to give injections. But this is something that the doctor and the patient should discuss.
Patricia Stark: [00:30:10] Alright. Dr. Marshall, thank you so much for all that great information and answering all of these questions. And that was our last question. And thank you all for submitting such insightful and thought-provoking questions. We hope that you’ve thoroughly enjoyed this evening’s broadcast. On behalf of Neurocrine Biosciences, I’m Patricia Stark. Thank you so much for joining us. Have a great night.
Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Pediatric: Androgen and GC Dose Reduction
Presented by
Kyriakie Sarafoglou,
MD
Professor, Department of Pediatrics
Divisions of Pediatric Endocrinology and Genetics & Metabolism
Department of Experimental & Clinical Pharmacology
University of Minnesota
Director, Center for Congenital Adrenal Hyperplasia and Noah’s Ark and Weiss Family CAH Research Fund and Endowment
University of Minnesota Masonic Children’s Hospital
Presented on March 12, 2025
Patricia Stark: [00:00:22] Good afternoon. I’m Patricia Stark, the host for this afternoon’s broadcast. I’d like to welcome you to the live presentation of Advancing Care in Classic Congenital Adrenal Hyperplasia, CAH: Study Insights from CAHtalyst Pediatric: Androgen and GC Dose Reduction. This afternoon’s broadcast is sponsored by Neurocrine Biosciences and presented by Dr. Kiki Sarafoglou, Professor of Pediatric Endocrinology and Pediatric Genetics and Metabolism at the University of Minnesota. Let’s get started. Here’s Dr. Sarafoglou.
Kyriakie Sarafoglou, M.D.: [00:00:58] Thank you for the introduction, and thank you, everyone, for joining the Congenital Adrenal Hyperplasia webinar. CAH is a rare autosomal recessive disorder with a worldwide estimated incidence of 1 in 14 to 1 in 18,000 live births. Approximately 95 percent of classic CAH cases are due to a deficiency of the 21-hydroxylase enzyme, which is an adrenal-specific enzyme required for cortisol and androsterone synthesis. Normally, there is a negative feedback inhibition between cortisol and both hypothalamic corticotropin-releasing factor and pituitary hormone ACTH. In CAH, because of cortisol deficiency, there is attenuation of cortisol-mediated negative feedback, which allows for excessive CRF drive from the hypothalamus, leading to increased ACTH secretion. Now, increase ACTH stimulation results in enlargement of the adrenal glands and production of cortisol precursors, which are then metabolized to the only pathway left, which is the androgen pathway.
[00:02:16] Now, in 21-hydroxylases specifically, the defect in this enzyme causes an increase in the steroids, primarily 17-hydroxyprogesterone, which is then converted to androstenedione and further down to testosterone. In addition, upstream of 17-OHP, progesterone accumulates, which can cause reproductive problems, especially in adult females with 21-hydroxylase deficiency. Downstream of the block in blue, there is deficient cortisol production. When the block is complete or nearly complete, there is deficient androsterone production, too.
[00:03:06] Patients with CAH face multiple comorbidities because of the disease and its treatment throughout their lives. So, CAH patients are at risk of adrenal crisis across their lifespan, which can be triggered by physical stress due to illness, trauma, or surgery. Infants with CAH are at the highest risk of salt-wasting and adrenal crisis, as they are most susceptible to intercurrent illnesses. Other presenting symptoms during infancy could be poor feeding, poor weight gain, and poor growth, which can be sign of inadequate glucocorticoid therapy. Now, on the other hand, glucocorticoid excess can lead to growth failure, weight gain, and early adiposity rebound, which sets the ground for increased comorbidities during adulthood, such as obesity, metabolic syndrome, and cardiovascular disease.
[00:04:07] During childhood, androgen excess can result in growth acceleration, visualization of the external genitalia, early development of pubic hair, precocious puberty, and advanced bone maturation, which can eventually lead to early growth plate fusion and, ultimately, short adult stature. Now, in order to suppress androgen excess, high glucocorticoid doses are typically used, which can lead to growth failure, decreased puberty growth spurt, and ultimately, again, short adult stature.
[00:04:45] In adulthood, both androgen access or glucocorticoid access can lead to impaired hypothalamic-pituitary gonadal axis and secondary hypogonadism and fertility impairment in both men and women. Also, chronic elevation of ACTH due to poor disease control can lead to the development of TARTS, also known as testicular adrenal rest tumors, which can develop as early as early as seven years of age. TARTS can lead to both decreased spermatogenesis and decreased testicular testosterone production. Females can also have adrenalized tumors in their ovaries, but it’s difficult to visualize them with a pelvic ultrasound. Other symptoms seen in females with CAH are acne, irregular menses, polycystic ovaries, and infertility, which are all related to androgen and progesterone excess.
[00:05:45] Now, chronic glucocorticoid excess can relate to osteopenia and osteoporosis. And may play a role in the high prevalence of mood disorders frequently encountered. In addition, adult patients with CAH are at an increased risk for cardiovascular disease and metabolic syndrome. Cardiovascular disease is the second most common cause of death behind adrenal crisis.
[00:06:15] Over the last 70 years, glucocorticoids have been the only option to treat CAH. Now, what is important to keep in mind is that glucocorticoid therapy serves two important functions in the treatment of CAH. Its first function is to replace deficient cortisol, as cortisol plays an important role in glucose and blood pressure regulation, immune function, sleep, mood regulation. In unaffected individuals, endogenous cortisol production ranges between 5 and 11 milligrams per meter square per day, with a mean of 7 milligrams per meter square per day. Now, the wide range is due to many factors such as weight, age, sex, puberty status, and variability of cortisone pharmacokinetics and glucocorticoid receptor sensitivity among individuals, just to name a few.
[00:07:17] Now, glucocorticoid therapy’s second function is to reduce ACTH-driven excess adrenal androgen production. And the ongoing challenge in treating patients with CAH is balancing excess androgens against the impact of chronic high-dose glucocorticoid therapy.
[00:07:40] Now, in broad terms, patients with CAH can be categorized into four quadrants based on their glucocorticoid dosing and their adrenal androgen response to glucocorticoid therapy. One quadrant has patients whose androgen are at goal with physiologic glucocorticoid dosing, which unfortunately does not represent the majority of patients with CAH. Another quadrant. Patients whose androgen are at goal but they require supraphysiologic glucocorticoid doses to suppress their androgens. A third quadrant has patients with the worst of all situations where androgens are not at goal, while the glucocorticoid dosing is supraphysiologic. And the fourth quadrant has patients whose androgens are not at goal while on physiologic glucocorticoid dosing.
[00:08:40] Typically, patients do not remain in one quadrant but oscillate between the various quadrants throughout their life. What this illustrates is the current glucocorticoid therapy is suboptimal and underscores the need of better treatment options to keep androgens under control and prevent chronic over-exposure to glucocorticoids.
[00:09:07] A new treatment option that has recently become available is crinecerfront. A corticotropic-releasing factor-one antagonist. Normally, the hypothalamic-pituitary-adrenal axis drives teratogenesis through binding of the hypothalamic CRF1 to its type-one receptor on corticotropes in the anterior pituitary. This, in turn, stimulates ACTH release and, subsequently, adrenal androgen production. As I mentioned earlier, in CAH, because of cortisol deficiency, there is attenuation of cortisol-mediated negative feedback, which allows for excessive CRF drive and ACTH secretion. In turn, increased ACTH stimulation drives excessive adrenal androgen production.
[00:10:01] Crinecerfront binds to the CRF1 receptor and, in a non-competitive manner, prevents the CRF1 from binding to the CRF receptor on the pituitary, leading to reduction of pituitary ACTH secretion. Less ACTH means less stimulation of the adrenal glands and a subsequent decrease in downstream adrenal androgen production. A decrease in androgen secretion could allow for glucocorticoid dose reductions to more physiological levels and circadian dosing in patients with CAH while maintaining control of their disease. Normally, cortisol is secreted in a classic circadian pattern. Cortisol is at its lowest levels at midnight, then begins to rise and peak overnight in the early morning hours and gradually decrease throughout the day. Instead, the highest dose can be given in the morning when the kids are the most active, and the lowest hydrocortisone dose in the evening for better growth and sleep outcomes. High hydrocortisone doses in the evening can interfere with growth hormone secretion and impairs sleep by increasing the time that it takes the child to fall asleep.
[00:11:30] Based on the results of the clinical trial that I will present it to you shortly, Crenessity was approved by the FDA as a non-steroidal adjunct therapy to glucocorticoid replacement to control androgen in adults and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. Crenessity is contraindicated in patients with hypersensitivity to crinecerfront or any excipients of Crenessity.
[00:12:05] Now, I’m going to discuss the data from the pediatric trial that led to the FDA approval of Crenessity. The CAHtalyst Pediatric Trial was conducted at 37 centers in the United States, Canada, and Europe. The objective of the CAHtalyst Pediatric Study was to evaluate the safety and efficacy of twice-a-day Crenessity. The study was designed as a Phase Three Multicenter Trial with a 28-week, randomized, double-blind, placebo-controlled treatment period.
[00:12:42] The baseline glucocorticoid and androstenedione levels of the participants are represented by the purple and yellow balloons. Participants were randomized to receive Crenessity or placebo and remain on the same glucocorticoid dose for four weeks. By keeping the participants on a stable glucocorticoid dose for four weeks, any reduction in androstenedione levels, which was the primary endpoint of the study, would be a direct result of the action of Crenessity. A key secondary endpoint, not shown here, was the change in serum 17-hydroxyprogesterone level from baseline to week four. All androstenedione and 17-hydroxyprogesterone measurements were performed prior to morning glucocorticoid dose.
[00:13:35] From week 4 to week 28, glucocorticoid doses were decreased stepwise to a target daily dose of less than 11 milligrams per meter square per day of hydrocortisone dose equivalents with the goal of achieving the lowest glucocorticoid dose by week 28 while maintaining androstenedione at levels similar to or better than baseline. The percent of glucocorticoid change from baseline to week 28 was a key secondary endpoint.
[00:14:10] On day one, patients were randomly assigned in a two-to-one ratio to receive Crenessity or placebo twice daily with morning and evening meals. The amount of the Crenessity dose was based on weight. Children weighing between 10 kilos to less than 20 kilos received 25 milligrams of Crenessity twice daily. Children weighing between 20 kilos to less than 55 kilos receive 50 milligrams twice daily. And children weighing equal or more than 55 kilos receive 100 milligrams twice a day.
[00:14:54] Hypothesis one was that during the 4-week stable glucocorticoid period, the addition of Crenessity would reduce androstenedione levels, but they would remain the same in the placebo group. Hypothesis two was that during the 24-week gradual glucocorticoid dose reduction period, the Crenessity group would be able to reduce glucocorticoid dosing at week 28 while androstenedione was maintained or improved relative to day one baseline. Whereas the placebo group would have no deduction in glucocorticoid dosing. In the pediatric clinical trial, because of the negative impact that rapid glucocorticoid dose reduction could have on growth and skeletal maturation in children, glucocorticoid dose reduction was gradually, adjusting every four weeks in one to four steps to a target dose of 8 to 10 milligrams per meter square per day in hydrocortisone equivalence, provided that androstenedione level was maintained or improve relative to day one baseline values. Blood samples were collected before the morning glucocorticoid dose at the end of every four weeks. Now, after the 24-week dose reduction period, the participants in the placebo crossover to receive Crenessity for a 24-week open-label treatment period.
[00:16:30] This was followed by open-label extension period. 100 pediatric participants completed the pediatric trial. The key inclusive criteria were a confirmed diagnosis of congenital adrenal hyperplasia in children age 2 to 17 years of age. All participants had to be on a total daily hydrocortisone or hydrocortisone equivalent greater than 12 milligrams per meter square per day for at least one month prior to screening. Androstenedione levels measured prior to the morning glucocorticoid dose had to be greater than the midpoint of the reference range based on sex and either- age for pre-puberty participants or for participants that were in puberty. 17-hydroxyprogesterone levels had to be above twice the upper limit of normal range.
[00:17:28] Key exclusion criteria were: known or suspected diagnosis of another form of classic CAH, any clinically significant medical condition or chronic disease that would interfere with the study endpoints, a history of bilateral adrenalectomy, hypopituitarism, or other conditions requiring chronic daily therapy with oral glucocorticoids.
[00:17:56] Demographics and baseline characteristics were generally similar between the Crenessity and placebo groups. Overall, about half the participants were female, and the mean age was 12 years. Of note, the youngest patient enrolled was four years old. More than 90 percent of all participants were on hydrocortisone, and the mean baseline glucocorticoid, daily dose, and hydrocortisone equivalents of both groups was supraphysiologic at 16.4 milligrams per meter square per day. Mean androstenedione and 17-hydroxyprogesterone concentrations were significantly elevated at baseline in both groups. This indicates that despite supraphysiologic glucocorticoid dosing, adrenal androgen control was poor. What this shows is that children in both the placebo and Crenessity groups were mostly in the third quadrant, where androgens are not at goal, and the glucocorticoid dosing is supraphysiologic.
[00:19:03] Notable medical conditions of interest of the participants upon entering to the study were that 55 percent- 58 percent of the kids who entered the study were either overweight or obese. At the scoring- that control of adrenal androgens is at the expense of high glucocorticoid exposure. In addition, high glucocorticoid exposure starting in infancy can lead to early adiposity rebound and makes children and young adults more susceptible to obesity. Also of note was that 6 percent of the male participants reporting testicular adrenal rest tumors upon entering the study. However, after baseline of the sonography, testicular adrenal rest tumors were found in 33 percent of the male patients. This tells us that testicular adrenal rest occur more frequently and at a young age, suggesting ACTH levels are chronically high in these patients between hydrocortisone doses and the early morning hours, even though they are on supraphysiologic dosing. And the chronic elevation of ACTH highlights the shortcomings of hydrocortisone therapy, the preferred glucocorticoid for treating children with CAH.
[00:20:34] Let us now discuss the efficacy data in the CAHtalyst Pediatric Study. As a reminder, hypothesis one was that the addition of Crenessity during the four-week stable glucocorticoid period would reduce androstenedione levels, whereas, in the placebo group, androstenedione levels would remain the same.
[00:20:58] At the end of the four-week glucocorticoid stable period, the Crenessity group had a substantial decrease in mean androstenedione of 405 to 208 nanograms per dL compared to the placebo group, which had an increase from 483 at baseline to 545 nanograms per dL at week 4. The study met its primary endpoint with a statistically significant least squares mean treatment difference of minus 267.8 nanograms per dL, which underscores the efficacy of Crenessity in reducing adrenal androgen.
[00:21:47] We saw a similar significant decrease in mean 17-hydroxyprogesterone levels at the end of week four in the Crenessity group, with levels going from 8,513 to 2,772 nanograms per dL compared with an increase in 17-hydroxyprogesterone levels in the placebo group. The study met a key secondary endpoint with a significantly squares mean treatment difference in 17-hydroxyprogesterone levels of minus 6,421 nanograms per dL between the Crenessity and placebo groups.
[00:22:30] Hypothesis two was to test that while gradually reducing the daily glucocorticoid dose over the 24-week period, children in the Crenessity group will maintain or improve androstenedione levels relative to baseline values. Whereas the placebo group would have no reduction in glucocorticoid dosing.
[00:22:55] The goal of the glucocorticoid dose reduction strategy in children was to reach a target dose of 8 to 10 milligrams per meter square per day of hydrocortisone equivalents at week 28, provided that androstenedione level was maintained or improved relative to the day one baseline values. Glucocorticoid dose reduction was done gradually, every four weeks, in up to four steps over the 24-week period, and was guided by the androstenedione level from the previous visit and the availability of glucocorticoid dose strengths needed for treatment. The target glucocorticoid dose reduction at each step was approximately 1 to 4 milligrams per meter square per day and followed the guideline of first reducing the most non-physiologic glucocorticoid time- type and timing.
[00:23:51] Since we are discussing glucocorticoid dose reduction, it’s important to recognize the risk of acute adrenal insufficiency or adrenal crisis with inadequate glucocorticoid therapy, especially in situations associating with increased cortisol need, such as acute intercurrent illnesses, serious trauma, or surgical procedures. Therefore, reduction of glucocorticoid dosing should be individualized with careful monitoring for persistent symptoms associating with cortisol deficiency, such as headache, fatigue, lack of concentration at school, and emotional ability. Glucocorticoid therapy should continue upon initiation and during treatment with Crenessity. Remember, Crenessity’s role is to reduce androgen levels between doses and in the early morning hours. But Crenessity does not have cortisol biologic functions on glucose, blood pressure regulation, and stress response. All children on Crenessity should have an emergency care plan reflecting the glucocorticoid dose changes on oral cortisol stress dosing guidelines.
[00:25:08] On week 28, after adjustments in glucocorticoid dose, the mean androstenedione in the Crenessity group, shown in purple, reduced from baseline by 89 nanograms per dL but rose in the placebo group by 111 nanograms per dL. Similarly, the mean 17-hydroxyprogesterone level in the Crenessity group reduced from baseline by 2,413 nanograms per dL. The placebo group also saw a reduction of 737 nanograms per dL.
[00:25:44] Overall, the daily glucocorticoid dose at the end of the 28-week study period reduced from 16.5 to 12.8 milligrams per meter square per day in the Crenessity group, a 17.5 percent decrease. While the mean glucocorticoid daily dose increased from 16.3 to 17 milligrams per meter square per day in the placebo group, a 6.1 percent increase. The least squares mean treatment difference of minus 23.5 percent between the Crenessity and placebo groups were statistically significant, which was a key secondary endpoint.
[00:26:30] Among Crenessity-treated pediatric participants, 30 percent achieved a physiologic glucocorticoid dose less than or equal to 11 milligrams per meter square per day in hydrocortisone equivalents at week 28 while maintaining or improving androstenedione levels from baseline. As compared with 0 percent glucocorticoid dose reduction in the placebo group. This is a clinically meaningful result, as it shows that Crenessity can help patients achieve a more physiologic glucocorticoid dosing while maintaining control of their adrenal androgens.
[00:27:00] To summarize this part of the results, Crenessity demonstrate efficacy across two critical aspects of CAH management. While keeping a stable glucocorticoid dose, Crenessity significantly reduced androstenedione and 17-hydroxyprogesterone levels at week 4. Crenessity significantly reduce glucocorticoid daily dose at week 28 while maintaining or improving androstenedione levels relative to day one baseline. 30 percent of participants treating with Crenessity were able to achieve a physiologic dose of glucocorticoids by week 28 versus 0 percent on placebo.
[00:27:47] And now, we move on to the safety data of the CAHtalyst Pediatric Study. The percentage of participants who had any treatment-emergent adverse events during the treatment period was similar in the two groups. 84 percent with Crenessity and 82 percent with placebo. Most treatment-emergent adverse events were mild to moderate in severity. Five participants experienced serious treatment-emergent adverse events, none of which were related to the trial regimen or led to discontinuation of the study drug. All participants recover or had resolution of symptoms. A total of 3 percent of Crenessity-treated subjects and no placebo-treated subjects discontinued treatment because of adverse reactions of abdominal pain, myalgia, or dizziness, which were considered unrelated to the study drug. No deaths occur during the trial period.
[00:28:58] This table compares the adverse reaction profile in patients treated with Crenessity versus placebo. Most adverse reactions were mild or moderate in intensity and spontaneously resolved. Headache, fatigue, and abdominal pain were the most frequent adverse events. These symptoms were more frequent in the Crenessity group and were most likely related to the glucocorticoid dose reduction. No safety concerns regarding Crenessity were reported with respect to vital signs, clinical laboratory tests, electrocardiographic findings, or neuropsychiatric assessments during the phase three pediatric trial.
[00:29:43] To summarize Crenessity safety and tolerability profile, the most common adverse reactions that occur in the Crenessity group and which were greater in the placebo group were headache, abdominal pain, fatigue, nasal congestion, and epistaxis. A total of 3 percent of Crenessity-treated subjects discontinued treatment because of adverse reaction of abdominal pain, myalgia, and dizziness. No adrenal crises were reported in pediatric patients being treated with Crenessity. 97 pediatric participants who completed the double-blind period continue on to the open-label period.
[00:30:27] Another important safety consideration to note was that a hypersensitivity reaction occur in a subject after three days of treatment with Crenessity, with symptoms of throat tightness, angioedema, and generalized rash. Therefore, if a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue Crenessity. Patients should be advised to seek immediate medical attention if they experience any signs or symptoms of hypersensitivity reactions, including rash, itching, swelling, or difficulty breathing.
[00:30:55] Again, in pediatric patients, the most common adverse reactions are headache, abdominal pain, fatigue, nasal congestion, and epistaxis. In adult patients, the most common adverse reactions are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia. You’re encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fdagov/MedWatch or call 1 800 FDA 1088. Please visit www.crenessity.com/hcp to view full Prescribing Information.
[00:31:36] To summarize. Crenessity reduces ACTH and the downstream production of adrenal androgens by selectively blocking the function of CRF1. Crenessity significantly reduce androgen and other precursor levels as measured by androstenedione and 17-hydroxyprogesterone at week 4 while glucocorticoid doses remain unchanged. Crenessity enabled reduction of the daily glucocorticoid dose while maintaining or improving androstenedione levels in pediatric patients with CAH. And finally, Crenessity demonstrate an excellent safety profile.
[00:32:23] Now, let’s move from the phase three pediatric trial to the dosing of Crenessity. Crenessity it is to be taken with a meal twice daily. And Crenessity is available as capsule and an oral solution for children. Capsules should be taken orally and swallow whole with liquid. An oral dosing syringe is required to measure and deliver the dose accurately when the liquid form of Crenessity is prescribed. Crenessity does not address the cortisol deficiency. Therefore, patients must continue taking glucocorticoids.
[00:33:03] Since Crenessity is a CYP3A4 substrate, concomitant use with a strong or moderate CYP3A4 inducer decreases Crenessity’s exposure, which can potentially reduce its efficacy. In patients that are taking a strong CYP3A4 inducer such as phenytoin or rifampin, both the morning and evening doses of Crenessity should be increased twofold. Now, if the patient is taking a moderate CYP3A4 inducer, only the evening Crenessity dose would be double. Specific dose regimens for adults 18 and older and children weighing equally to greater than 55 kilos, the recommended dose is 100 milligrams twice daily for a total of 200 milligrams per day. For children weighing 2 kilo- 20 kilos to less than 55 kilos, the dose is 50 milligrams twice daily for a total of 100 milligrams per day. And for children weighing 10 to less than 20 kilos, the dose is 25 milligrams twice daily for a total of 50 milligrams per day. Crenessity is available in 50 milligrams and 100 milligrams capsule as an oral solution of 50 mg/mL.
Patricia Stark: [00:34:20] Well, thank you very much, Doctor. And a warm thank you, really, to Dr. Sarafoglou. So much great information there. We do hope that you thoroughly enjoy this afternoon’s broadcast. On behalf of Neurocrine Biosciences, I’m Patricia Stark. Thank you so much for joining us.
Congenital Adrenal Hyperplasia (CAH): Study Insights from CAHtalyst™ Adult With 8-Week Rapid Protocolized GC Dose Reductions
Presented by
Richard J. Auchus,
MD, PhD
Professor of Internal Medicine
MEND Division
University of Michigan Medical School
Presented on January 23, 2025
Patricia Stark: [00:00:17] Well. Good evening. I’m Patricia Stark, the host for tonight’s broadcast. I’d like to welcome you to the live presentation of Advancing Care in Classic Congenital Adrenal Hyperplasia (CAH): Study Insights from Catalyst Adult. This evening’s broadcast is sponsored by Neurocrine Biosciences and presented by Dr. Richard Joseph Auchus, professor of pharmacology and internal medicine at the University of Michigan Medical School. So let’s get started. Here’s Dr. Auchus.
Richard Joseph Auchus, M.D., Ph.D.: [00:00:47] Well, thank you Patricia. Good evening, everyone, and thanks for joining. Congenital adrenal hyperplasia, or CAH, is a rare autosomal recessive disorder. Worldwide, the incidence of classic CAH is about 1 in 14 to 18,000 live births. Most commonly, the disease is due to a deficiency of the enzyme 21 hydroxylase, about 95 percent of cases. This is an enzyme that’s required for the biosynthesis of both cortisol and aldosterone. Now, the loss of, or attenuated cortisol mediated negative feedback that the body normally has allows for excessive CRF drive from the hypothalamus corticotropin-releasing factor, and that drives excessive ACTH secretion from the pituitary. And this ACTH leads to the enlargement of the adrenal and to excessive production of cortisol precursors, which are metabolized onto the only pathway left, which is to androgens. So it is congenital. It’s a genetic defect. It involves the adrenal specifically in the cortisol pathway. And there is hyperplasia as a result of the lack of cortisol and the elevated ACTH.
[00:02:03] Now in 21 hydroxylase specifically, the defect in that enzyme then causes an increase in the steroids in orange, primarily 17 hydroxy progesterone or 17-OHP, which is then converted to androstenedione and further down to testosterone inactive androgen. In addition, upstream of 17-OHP, progesterone accumulates and this also causes reproductive problems, particularly in the adult females with 21 hydroxylase deficiency. And of course, downstream of the block in blue, there is deficient cortisol production, and when the block is complete or nearly complete, deficient aldosterone production.
[00:02:46] Now patients with CAH and their families face multiple challenges and comorbidities throughout their lifetime. Because of the cortisol deficiency, there is a risk of adrenal crisis with intercurrent illness throughout lifetime, particularly in infancy. In fact, babies can have salt wasting adrenal crisis even when they’re not sick because of the severe deficiency in cortisol and aldosterone. They also experience poor feeding, poor weight gain, and the girls have atypical genitalia at birth because of the androgen excess in fetal life.
[00:03:22] Throughout childhood, the adrenal androgens can drive accelerated growth and advancement of the Bone Age, which leads to early fusion of the growth plates and short stature in adulthood. They can also have poor growth because of the exposure to the typical doses of glucocorticoids required to control the androgen excess, and they can also have problems with puberty, either early puberty or delayed puberty as a result of the dysregulation of the adrenal hormones and the cortisol treatment that they receive.
[00:03:56] Now in adulthood, the problems with the pubertal axis continue, and fertility impairment is common in both men and women with classical CAH. They also have a high prevalence of mood disorders, possibly from the chronic treatment with high doses of glucocorticoids, and those glucocorticoids can also cause osteopenia and osteoporosis. We already talked about the reduced adult stature and increased cardiovascular risk. The second most common cause of death in patients with CAH is cardiovascular disease behind adrenal crises. The women suffer from hirsutism, acne, irregular menses, and polycystic ovaries, all related to the androgen and progesterone excess, and the males also have fertility problems, both from suppression of the gonadal axis but also from the development of testicular adrenal rest tumors in their testes.
[00:04:56] So 60, 70 years ago, Lawson Wilkins decided that he could treat congenital adrenal hyperplasia with glucocorticoids. But there’s two purposes of this cortisol treatment. So one is to replace the cortisol deficiency. And the daily cortisol production rate is about 7mg/m² per day. And a dose of about that much is required to replace that deficiency. But you also use the glucocorticoids to suppress the ACTH and the adrenal androgen production, and this requires significantly more glucocorticoids. I think the way that I think about this is that the normal cortisol production is micrograms per deciliter, whereas androgens are ng/dl. So you really have to suppress the adrenal steroid production substantially to get the androgens down to what’s normal, particularly in children’s where they make very little androgens, or none. So, so then it becomes a difficult balancing act, particularly throughout childhood of titrating the glucocorticoid dose. Too little glucocorticoid and the androgens rise and advance the bone age. Too much glucocorticoid and the child doesn’t grow well, even though the androgens are controlled. So this is challenging.
[00:06:20] Now in addition, mineralocorticoid replacement therapy is required, and we use fludrocortisone acetate to replace the aldosterone deficiency in the majority of patients with classic CAH. But it is a difficult balancing act, and you can think of patients being in four quadrants. And we want to have patients in the one quadrant where their androgens are at goal with a physiologic dose of glucocorticoids. Now unfortunately this is the minority of patients. There’s only a handful of people that I know of that can have androgens at goal with a physiologic dose of glucocorticoids.
[00:06:55] You can also imagine two other groups. Either the androgens are at goal, but it requires supraphysiologic glucocorticoids to suppress those androgens. Or the androgens are not at goal, but they’re on a lower dose of glucocorticoids that can be considered physiologic. And finally, unfortunately, there are a lot of people who have the worst of all situations, which are the androgens not being at goal and the glucocorticoid dose is still supraphysiologic. So despite that super physiologic dose, we can’t get their disease under control.
[00:06:25] And furthermore, patients can oscillate between these various states throughout their life. And so what this illustrates is the failure of traditional glucocorticoid-only therapy to consistently manage patients, both to prevent the long-term complications of glucocorticoid therapy and to keep their androgens under control for their long-term health outcomes.
[00:07:50] Now, I and my colleagues have been working for some time now to come up with other treatments that are not glucocorticoids to control this disease. And so one strategy is using crinecerfont, which is a potent and selective antagonist of the corticotropin-releasing factor type one receptor or the CRF1 receptor, which is the receptor that’s expressed on the cells in the anterior pituitary gland that make ACTH. So in the normal state, what’s shown here on, on the left is the hypothalamus produces a normal amount of CRF, which binds to its receptors on the anterior pituitary gland and produces a normal amount of ACTH, which leads to a small amount of systemic androgens coming from the adrenal gland. In the CAH patient with the loss of negative feedback, then there is excessive drive, the hypothalamus makes more CRF. That drives the pituitary to make more ACTH, and then there’s an excess of adrenal androgens produced.
[00:08:59] Now crinecerfont binds to that CRF1 receptor in a noncompetitive manner with CRF and it prevents the action of CRF on that receptor. And that reduces the amount of ACTH that’s produced from the same amount of CRF, and therefore reduces the amount of androgens that the adrenal makes. So we hypothesize that reduced androgen production through CRF antagonism might enable glucocorticoid dose reduction to more physiologic levels while maintaining control of the disease.
[00:09:37] Now based on the work I’m going to show you, Crenessity or crinecerfont, was approved by the FDA, and it is indicated as an adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. The contraindication is that Crenessity is contraindicated in patients with hypersensitivity to crinecerfont, or to any of the excipients in Crenessity. So now I’m going to show you the data that led to this approval of Crenessity.
[00:10:17] So the adult study was called the CAHtalyst Adult Study. Not surprisingly, the pediatric study was the CAHtalyst Pediatric study, and it involved a protocolized glucocorticoid dose reduction. So this was a complicated study that involved 24 weeks with a randomized, double-blind, placebo-controlled, multicenter, phase three trial. We started with patients who were taking a glucocorticoid dose that was high. It was at least 13mg/m² per day, which is above the normal cortisol production rate plus two standard deviations. And their androstenedione levels had to be not suppressed. So this is depicted by the red and the yellow balloons, respectively.
[00:11:02] Now what we first did, they came into the study on a variety of, of glucocorticoid regimens, some hydrocortisone, some prednisone. And we left that glucocorticoid dose constant for four weeks and added either Crenessity or placebo to the patients. And we saw what that did to the androstenedione, which was our primary biomarker to demonstrate reduction of adrenal androgens by Crenessity. So that was done for four weeks. And that was a key secondary endpoint, the reduction in androstenedione in the crinecerfont group compared to placebo. We also looked at 17 hydroxy progesterone change from baseline at four weeks. But again this was where the glucocorticoid dose was kept whatever they came into the trial on.
[00:11:55] Then we dropped the glucocorticoid dose. So that’s the red balloon going down. And we allowed the androstenedione to come up, but we tried to keep it below or at baseline compared to day one. So we would let the androstenedione drift back up but that was at the expense of reducing the glucocorticoid dose. So the primary endpoint for this study was the glucocorticoid dose reduction, the change from baseline at week 24 as long- provided that the androstenedione was kept at or below baseline. There was a key secondary endpoint, which was the percent of patients who reached the physiologic range of glucocorticoid dosing, which was defined as 11mg/m² per day, which is the median plus two standard deviations of cortisol production in normal individuals.
[00:12:48] Okay. So three phases to this trial. So hypothesis one was that crinecerfont addition will reduce androstenedione. And hypothesis two is that that reduction will allow for reduction in glucocorticoid dose. And that glucocorticoid dose reduction was done over a very short time, over eight weeks. So every two weeks, people could have a reduction in their in their glucocorticoid dose from whatever they came in the trial on with the goal of getting it down to 8 to 10mg/m² per day. So a very steep reduction in four steps or less.
[00:13:28] And then in the following 12 weeks, before the primary endpoint time at week 24, if the androstenedione was higher than baseline, we could raise the glucocorticoid dose to optimize glucocorticoid therapy. And the prediction would be that the crinecerfont group would keep the glucocorticoid dose down, but the placebo group would have to go up. After that, the placebo arm was crossed over to receive Crenessity, and after a year, there was an open-label extension phase where patients could continue. So at the bottom, I’m showing you, hypothetically, what we expect to see that the androstenedione levels during the first four weeks when the glucocorticoid dose was kept constant would drop in the crinecerfont group, but not the placebo group. And then we would reduce the glucocorticoids on a schedule in both groups and the androstenedione would come up somewhat. And then we would adjust that dose over the following 12 weeks to keep the androstenedione below baseline and see how low the glucocorticoids got.
[00:14:35] Okay. So 182 adult participants were enrolled in this study. The key inclusion criteria were a confirmed diagnosis of classic 21 hydroxylase deficiency, the supraphysiologic glucocorticoid dose of greater than 13mg/m² of hydrocortisone dose equivalent, with conversion factors for people taking prednisone, prednisolone, and dexamethasone. They had to be on that regimen for a stable one-month period of time. The key exclusion criteria were some other condition other than CAH that required long-term glucocorticoid treatments such as psoriasis, known or suspected diagnosis of some other form of classic CAH, and evidence of substantial glucocorticoid overtreatment, meaning that their androstenedione was below the normal range, below the lower limit of the normal range on screening.
[00:15:33] So the two groups that received Crenessity or placebo were well matched, 222 received Crenessity, 60 received placebo. About half of them were women. Their average age was about 30. They were overweight, with an average body mass of 80kg. Their average glucocorticoid daily dose was 17 to 18mg/m² per day, which equals about 32 mg total per day. So it’s about twice physiologic. About 60 percent were receiving hydrocortisone alone. Another 30 percent were receiving other glucocorticoids with or without hydrocortisone, and 10 to 15 percent were receiving dexamethasone with or without another drug. Now, in this laboratory, the mean androstenedione, the upper limit of normal, was about 200 ng/dl. And the study participants were about 600 ng/dl. So about three times the upper limit of normal. And the 17 hydroxyprogesterone was 9 to 10,000. So these people are in that fourth quadrant, largely. These are people who are in poor control despite a high dose of glucocorticoids.
[00:16:44] Alright, furthermore, about two-thirds of the men had testicular adrenal rest tumors. About half or more of the women had menstrual irregularities. There was a high percentage of women that had hirsutism and acne. There was a high percentage of people who had anxiety and depression and other mood disorders and complications that we think of in older people; osteopenia, hypertension, hyperlipidemia, osteoporosis, were significantly prevalent in this group at an average age of 30 years old, so not doing very well.
[00:17:17] So let me review the efficacy in the CAHtalyst Adult Study with this protocolized glucocorticoid dose reduction. So again, hypothesis one that was tested in the first four weeks while we held the glucocorticoid dose constant, was that in a placebo-controlled setting, we could show that Crenessity reduced the adrenal androgens better than placebo. Now, I will say that there is a warning that a hypersensitivity reaction, including throat tightness, angioedema a generalized rash, occurred in a subject after three days treatment with Crenessity. So therefore, if a clinically significant hypersensitivity reaction occurs, you should initiate appropriate therapy and discontinue Crenessity.
[00:18:05] Alright, so in the first four weeks we saw a- basically a 300 ng/dl, or a 50 percent reduction in androstenedione in the Crenessity group. No change or a slight rise in androstenedione in the placebo arm. And that equated to a least squared mean difference at week four of -345 ng/dl in the Crenessity arm versus placebo, which was highly statistically significant. In parallel, we saw a reduction of 17 hydroxyprogesterone of about 6000 ng/dl, minimal change in placebo. So the least squared mean difference was almost 6000 ng/dl, also significant.
[00:18:53] Okay. So now we’ve done hypothesis one. So hypothesis two was to show that we could reduce the glucocorticoid dose and keep that androstenedione from rising back to above baseline. So from week 4 to week 12 every two weeks, we made a dose reduction to a target of 8 to 10mg/m² per day, and then went back up as necessary in the following 12 weeks to the endpoint, the primary endpoint at week 24, which was the reduction in glucocorticoid dosing. So the study goal was to hit at least 11mg/m² per day or less, while maintaining that androstenedione at baseline or better in those with that glucocorticoid reduction of four steps and that maintenance- that optimization phase to week 24.
[00:19:48] Now, importantly, what I want to emphasize is that we tried to decrease the most nonphysiologic dose and type of glucocorticoid first. So for example, if someone was taking dexamethasone, which is very nonphysiologic, we would try to switch them to prednisone or hydrocortisone. If they were taking a bedtime dose of prednisolone with hydrocortisone during the day, the first thing we would do is try to stop the bedtime prednisolone. Those are the doses that are best for controlling the androgens, but they are the most toxic and the least physiologic. So we actually use the strategy that would work against our achieving the primary endpoint and to see what we could accomplish with crinecerfont.
[00:20:35] Now as we did this study, it’s important to recognize that the risk of acute adrenal insufficiency or adrenal crisis with inadequate concomitant glucocorticoid therapy persists. So acute adrenal insufficiency or adrenal crisis, which is potentially life threatening, can occur in patients with underlying adrenal insufficiency who are taking inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intermittent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with Crenessity. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dose glucocorticoids in case of increased cortisol need. So in the trial we never dropped the dose to less than physiologic. And we always kept people informed of what their stress dosing regimen was, which did change during the trial as we reduced the glucocorticoid dose for day-to-day treatment.
[00:21:45] Okay, now we were supposed to keep the androstenedione at or below baseline by week 24. And we succeeded in doing this in the Crenessity group. But the placebo group actually rose another 388 ng/dl. Now, the participants in this trial were trying to get their glucocorticoid dose reduced. The investigators were hoping to reduce the glucocorticoid, so there was some reluctance in going back up on the glucocorticoid dose in the placebo group. And that’s something to bear in mind. Now, there was a statistical penalty applied to this. But, but I want you to bear this in mind when we go through the primary endpoint.
[00:22:30] So despite what I just showed you, the reduction in glucocorticoid dose was greater with crinecerfont than with placebo. A 28.1 percent reduction with Crenessity, which is about a nine milligram per day hydrocortisone dose reduction versus 11.6 percent with placebo. And you can see that the nadir was at week 12 in placebo and it drifted back up, whereas the dose was kept down from weeks 12 to week 24 with Crenessity. So the least squared mean dose reduction of glucocorticoids of the Crenessity group versus placebo was 17 percent, and that was the highly statistically significant and the primary endpoint was met.
[00:23:19] So the percentage of patients that achieve that less than 11mg/m² per day in the crinecerfont group was 63 percent. You can see that it was quite stable from week 12 to week 24, and it peaked at week 12 in the placebo group and gradually drifted back down. And it was only 18 percent at the end of the study. This was also statistically significant.
[00:23:43] So we demonstrated efficacy across two distinct and critical aspects of CAH management. First was the androgen reduction that Crenessity significantly reduced androstenedione at week four and concurrently reduced 17 hydroxyprogesterone while holding the glucocorticoid dose stable. And then after that, we reduced the glucocorticoid dose Crenessity significantly, allowed reduction of glucocorticoid daily dosing at week 24, while maintaining or improving androstenedione relative to the baseline. 63 percent of participants on Crenessity were able to achieve a physiologic glucocorticoid dose by week 12, versus 18 percent on placebo.
[00:24:25] I want to go through the safety data now, and the most important thing to know about safety is that in adult patients, the most common adverse reactions that occurred in at least 4 percent for Crenessity and greater than placebo are fatigue, headache, dizziness, arthralgias, back pain, decreased appetite, and myalgias.
[00:24:47] About 80 percent of the participants in both arms experienced any treatment emergent adverse event. There were four serious adverse events in the Crenessity group, none in the placebo, and none of those serious adverse events were judged being related to the study drug. There were four adverse events that led to study drug discontinuation in the Crenessity group. Most of the adverse events were either mild or moderate and resolved spontaneously.
[00:25:20] This is comparing the adverse event profile in patients treated with Crenessity versus placebo. And as I mentioned before, fatigue, headache, dizziness, arthralgias, back pain, decreased appetite, and myalgias. Many of these are the same things that we see with the glucocorticoid withdrawal syndrome, and could be related to the glucocorticoid dose reduction in both the Crenessity and placebo groups. The, the- there were no safety concerns related to vital signs, clinical laboratory tests, electrocardiographic findings, or neuropsychiatric assessments with Crenessity in the phase three trial.
[00:26:00] I think this is one of the most telling statistics about the study. 96 percent of the adults participants completed the 24-week, double-blind, placebo-controlled period of the phase two trial with 117 of 122 whether they were on the drug or placebo. And I think that is a testament to how dedicated these patients were to getting a new drug approved, how desperate the community is for seeing better treatment, and how motivated the investigators are to getting a new treatment for this vexing disease. A total of 3 percent of Crenessity treated subjects and no placebo treated subjects discontinued because of adverse reactions which were restlessness, apathy, dyspepsia, nausea, and vomiting. 174 of the 182 adult participants continued on after a whole year into the open-label extension, and several of them are still in the open-label extension now. 1.6 percent of patients taking Crenessity experienced an adrenal crisis. No patients in the placebo arm experienced an adrenal crisis, however, 1.7 percent experienced adrenal insufficiency. So it’s important for you to talk with your patients about the importance of continuing glucocorticoid dosing while taking Crenessity and have a plan for glucocorticoid stress dosing and for rescue parenteral hydrocortisone injection.
[00:27:30] In pediatric patients, the most common adverse reactions are headache, abdominal pain, fatigue, nasal congestion, and epistaxis. You are encouraged to report negative side effects of all prescription drugs to the FDA. Visit MedWatch at FDA.gov/MedWatch, or call 1-800-FDA-1088.
[00:27:53] So, to summarize, Crenessity reduces androstenedione levels and enables a reduced glucocorticoid dose while maintaining or improving androstenedione levels in adult patients with CAH. As a novel mechanism of action by selectively blocking the function of CRF1, Crenessity directly reduces ACTH and the downstream production of adrenal androgens. Proven efficacy in this phase three trial, Crenessity enables significantly reduced glucocorticoid daily dose while maintaining or improving androstenedione levels in adult patients with CAH. Crenessity significantly reduced androstenedione at week four and concurrently reduced 17 hydroxyprogesterone, while glucocorticoid doses remain unchanged. And safety, the most common adverse reactions in adults are fatigue, headache, dizziness, arthralgias, back pain, decreased appetite, and myalgias.
[00:28:49] Dosing is pretty simple. The drug is taken twice, twice a day with a morning and evening meal. Crenessity must be taken with a meal. You shouldn’t take it with a cup of black coffee. So, morning and evening meal. It’s available as capsules or an oral solution for children. The capsules should be swallowed whole with liquid and not chewed. The oral solution should be taken with an oral syringe for precise dosing. Do not reduce the glucocorticoid dose below the dose required to replace the cortisol deficiency.
[00:29:23] Dosing considerations, the only one is that Crenessity is a CYP3A4 substrate, and so concomitant use with a strong or moderate CYP3A4 inducer will decrease Crenessity exposure, which may reduce its efficacy. So in patients who are taking a strong 3A4 inducer, something like phenytoin or rifampin, you should increase both the morning and evening dosages twofold. Whereas if they’re taking a moderate CYP3A4 inducer, you should only double the evening dose. And so the dose is in adults 18 and older and in children weighing greater than 121 pounds, 100 mg twice daily, for a total of 200 mg a day. For children weighing 44 to 121 pounds, the dose is 50 mg twice daily. And for children weighing 22 to 44 pounds, the dose is 25 mg twice daily. The Crenessity is available in both 50 and 100 mg capsules, and as an oral solution of 50 mg/mL. There is no dosage change with concomitant CYP3A4 substrates, only with CYP3A4 inducers.
Patricia Stark: [00:30:35] We hope that you thoroughly enjoyed this evening’s broadcast. On behalf of Neurocrine Biosciences, I’m Patricia Stark, and thanks so much again. Have a great night.
These physicians have been compensated by Neurocrine.